Your Good Partner in Biology Research

重組蛋白

產(chǎn)品名稱 貨號(hào) 規(guī)格
Recombinant Chromobacterium violaceum UDP-3-O-[3-hydroxymyristoyl] N-acetylglucosamine deacetylase (lpxC) CSB-YP762918CKA
CSB-EP762918CKA
CSB-BP762918CKA
CSB-MP762918CKA
CSB-EP762918CKA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Chromobacterium violaceum 4-hydroxythreonine-4-phosphate dehydrogenase (pdxA) CSB-YP762919CKA
CSB-EP762919CKA
CSB-BP762919CKA
CSB-MP762919CKA
CSB-EP762919CKA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Chromobacterium violaceum Holliday junction ATP-dependent DNA helicase RuvB (ruvB) CSB-YP762920CKA
CSB-EP762920CKA
CSB-BP762920CKA
CSB-MP762920CKA
CSB-EP762920CKA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Chromobacterium violaceum 50S ribosomal protein L23 (rplW) CSB-YP762921CKA
CSB-EP762921CKA
CSB-BP762921CKA
CSB-MP762921CKA
CSB-EP762921CKA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Chromobacterium violaceum 50S ribosomal protein L29 (rpmC) CSB-YP762922CKA
CSB-EP762922CKA
CSB-BP762922CKA
CSB-MP762922CKA
CSB-EP762922CKA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Chromobacterium violaceum 50S ribosomal protein L18 (rplR) CSB-YP762923CKA
CSB-EP762923CKA
CSB-BP762923CKA
CSB-MP762923CKA
CSB-EP762923CKA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Chromobacterium violaceum 30S ribosomal protein S4 (rpsD) CSB-YP762924CKA
CSB-EP762924CKA
CSB-BP762924CKA
CSB-MP762924CKA
CSB-EP762924CKA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Chromobacterium violaceum 50S ribosomal protein L25 (rplY) CSB-YP762925CKA
CSB-EP762925CKA
CSB-BP762925CKA
CSB-MP762925CKA
CSB-EP762925CKA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Chromobacterium violaceum Dephospho-CoA kinase (coaE) CSB-YP762926CKA
CSB-EP762926CKA
CSB-BP762926CKA
CSB-MP762926CKA
CSB-EP762926CKA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Chromobacterium violaceum Guanylate kinase (gmk) CSB-YP762927CKA
CSB-EP762927CKA
CSB-BP762927CKA
CSB-MP762927CKA
CSB-EP762927CKA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Chromobacterium violaceum Thymidylate kinase (tmk) CSB-YP762928CKA
CSB-EP762928CKA
CSB-BP762928CKA
CSB-MP762928CKA
CSB-EP762928CKA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Chromobacterium violaceum 30S ribosomal protein S9 (rpsI) CSB-YP762929CKA
CSB-EP762929CKA
CSB-BP762929CKA
CSB-MP762929CKA
CSB-EP762929CKA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Chromobacterium violaceum 50S ribosomal protein L19 (rplS) CSB-YP762930CKA
CSB-EP762930CKA
CSB-BP762930CKA
CSB-MP762930CKA
CSB-EP762930CKA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Chromobacterium violaceum Phosphoribosylformylglycinamidine cyclo-ligase (purM) CSB-YP762931CKA
CSB-EP762931CKA
CSB-BP762931CKA
CSB-MP762931CKA
CSB-EP762931CKA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Chromobacterium violaceum Deoxycytidine triphosphate deaminase (dcd) CSB-YP762932CKA
CSB-EP762932CKA
CSB-BP762932CKA
CSB-MP762932CKA
CSB-EP762932CKA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Chromobacterium violaceum Adenylosuccinate synthetase 2 (purA2) CSB-YP762933CKA
CSB-EP762933CKA
CSB-BP762933CKA
CSB-MP762933CKA
CSB-EP762933CKA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Chromobacterium violaceum UPF0060 membrane protein CV_3485 (CV_3485), partial CSB-YP762934CKA1
CSB-EP762934CKA1
CSB-BP762934CKA1
CSB-MP762934CKA1
CSB-EP762934CKA1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Chromobacterium violaceum Chemotaxis response regulator protein-glutamate methylesterase of group 3 operon (cheB3) CSB-YP762935CKA
CSB-EP762935CKA
CSB-BP762935CKA
CSB-MP762935CKA
CSB-EP762935CKA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Chromobacterium violaceum 50S ribosomal protein L32 (rpmF) CSB-YP762936CKA
CSB-EP762936CKA
CSB-BP762936CKA
CSB-MP762936CKA
CSB-EP762936CKA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Chromobacterium violaceum Probable Fe (2+)-trafficking protein (CV_3356) CSB-YP762937CKA
CSB-EP762937CKA
CSB-BP762937CKA
CSB-MP762937CKA
CSB-EP762937CKA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長(zhǎng)度(全長(zhǎng)或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對(duì)其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見問題。您可以單擊以下鏈接查看。http://m.cstxtech.com/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對(duì)CUSABIO的蛋白質(zhì)有任何疑問,涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們?cè)诰€留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>